Quarterly ResultJul 14, 2026, 07:36 AM
AngioDynamics Reports Record FY26 Results; Med Tech Sales +18.4%
AI Summary
AngioDynamics announced record financial results for fiscal year 2026, with pro forma net sales of $320.2 million, up 9.4% year-over-year. The Med Tech segment achieved 18.4% growth, marking its seventh consecutive quarter of double-digit growth and contributing to positive adjusted EBITDA of $13.2 million. The company also reported significant clinical and regulatory milestones for its NanoKnife, AlphaVac, and AngioVac systems, and provided positive fiscal year 2027 guidance.
Key Highlights
- FY26 Pro Forma Net Sales: $320.2 million, up 9.4% YoY.
- FY26 Med Tech Net Sales: $150.0 million, up 18.4% YoY.
- FY26 Adjusted EBITDA: $13.2 million; Q4 Adjusted EBITDA: $3.3 million.
- FY26 Adjusted Loss Per Share: $0.24.
- Ended FY26 with $53.9 million in cash and a debt-free balance sheet.
- Received FDA IDE approvals for APEX-Return (AlphaReturn) and PAVE (AngioVac) studies.
- NanoKnife secured Medicare coverage and Category I CPT codes for prostate/liver cancer.
- FY27 Net Sales Guidance: $336.0 million - $341.0 million; Med Tech Sales Growth: 12-15%.
Price Impact
More from ANGO